Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02926833
Title A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA-6)
Acronym ZUMA-6
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Kite Pharma, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope Duarte California 91010 United States Details
Stanford Cancer Center Palo Alto California 94305 United States Details
H Lee Moffitt Cancer Center Tampa Florida 33612 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
University of Texas MD Anderson Cancer Center Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field